APA
Peña Cardelles, Juan Francisco & Garrido Martínez, Pablo & Salgado Peralvo, Angel Orión & Cebrián Carretero, José Luis & Pozo Kreilinger, José Juan & Moro Rodríguez, José Ernesto .Oral mucositis. Is it present in the immunotherapy of the immune checkpoint pd1/pd-l1 against oral cancer? A systematic review.
ISO 690
Peña Cardelles, Juan Francisco & Garrido Martínez, Pablo & Salgado Peralvo, Angel Orión & Cebrián Carretero, José Luis & Pozo Kreilinger, José Juan & Moro Rodríguez, José Ernesto. Oral mucositis. Is it present in the immunotherapy of the immune checkpoint pd1/pd-l1 against oral cancer? A systematic review.
https://hdl.handle.net/20.500.12080/25304
Resumen:
Background: Oral mucositis (OM) is a painful lesion that takes place in the mucosa of the oral cavity, usually its
etiology is associated with drug therapies in cancer patients. It is presented as well-defined ulcers whose painful
symptomatology sometimes implies the suspension of oncological treatment or parenteral feeding, being therefore
an important adverse effect, marking the evolution of these types of therapies against cancer. The present
work aim is to know the prevalence of oral mucositis in oral cancer immunotherapy compared to its prevalence
in standard therapy.
Material and Methods: A protocol was developed for a systematic review following PRISMA® guidelines and a
focused question (PICO) was constructed. A comprehensive literature search was conducted on electronic databases
including PubMed, the SCOPUS database, the Cochrane library and the Web of Science (WOS).
Results: Six clinical trials were included that met the different inclusion criteria. In these articles, a discrepancy
between the prevalence of OM in patients treated with chemotherapy and patients treated with immunotherapy
related to the immune checkpoint PD-1/PD-L1 (Nivolumab and Pembrolizumab) was observed.
Conclusions: The prevalence of oral mucositis is lower in new immunotherapy with monoclonal antibodies against
oral cancer than drugs used so far (chemotherapy drugs [methotrexate, cisplatin] as well as cetuximab). However,
more studies should be carried out to confirm these data.
Key words: Oral mucositis, PD1, PD-L1, oral cancer, immunotherapy.